Hanmi Pharmaceutical Appoints First External CEO as Sangyeon Hwang Takes the Helm
Leadership Change as Jaehyun Park's Reappointment Fails
La Defense Partners Joins Hanmi Science Board... Attention on Shifts in Management Structure
For the first time since its founding, Hanmi Pharmaceutical has appointed a CEO from outside the company, signaling a shift in its management structure.
From the left, Jae-kyo Kim, CEO of Hanmi Science, and Sang-yeon Hwang, newly appointed CEO of Hanmi Pharmaceutical, are responding to reporters' questions at Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul on the 31st. Photo by Jeong-yeon Park
View original imageOn the 31st, Hanmi Pharmaceutical passed an agenda item appointing Sangyeon Hwang, CEO of HB Investment Private Equity, as the new CEO during its 16th regular general shareholders' meeting held at its headquarters in Songpa-gu, Seoul. All other agenda items, including the appointment of Nayoung Kim as inside director and Taejun Han and Taeyoon Kim as outside directors, were also approved as originally proposed.
The reappointment of the previous CEO, Jaehyun Park, was not successful. Former CEO Park tendered his resignation in mid-March amid ongoing conflicts with Dongguk Shin, chairman of Hanyang Precision and the largest individual shareholder of the holding company Hanmi Science.
On the same day, during the Hanmi Science shareholders' meeting, Namgyu Kim, CEO of private equity firm La Defense Partners, was newly appointed as a non-executive director. With this, La Defense Partners will now participate directly in the board of directors.
La Defense Partners is part of the so-called "four-party alliance" along with Chairman Shin, Youngsook Song, chairwoman of Hanmi Group, and Vice Chairman Joohyun Lim. Having secured a majority stake in Hanmi Science, the alliance has become a key pillar of the group’s management rights. Industry observers interpret La Defense Partners’ entry to the board as a move to both strengthen its influence over group decision-making and serve as a check on Chairman Shin, the largest shareholder. In particular, in light of recent controversies regarding management intervention, there is growing attention to whether the internal balance of the four-party alliance will shift.
Previously, Chairman Shin expanded his influence by acquiring additional Hanmi Science shares through off-market purchases. As a result, he increased his and his special affiliates’ combined stake to around 30%, consolidating his position as the largest single shareholder. During this process, conflicts with former CEO Park surfaced. In addition, as debate over management intervention intensified, concerns have been raised about the possibility of fissures within the four-party alliance.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
During the shareholders' meeting held in the morning, Hanmi Science stated that internal issues regarding the corporate governance structure had been resolved. Jaekyo Kim, CEO of Hanmi Science, said, "As a holding company, Hanmi Science conveyed its opinions to the Hanmi Pharmaceutical board of directors, and please understand that issues related to corporate governance represent the results of an agreement."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.